(0.25%) 5 112.52 points
(0.21%) 38 319 points
(0.24%) 15 966 points
(-1.42%) $82.66
(3.85%) $1.997
(0.03%) $2 347.90
(0.01%) $27.54
(3.53%) $954.65
(-0.19%) $0.933
(-0.34%) $10.99
(-0.44%) $0.797
(1.49%) $93.24
@ $6.86
发出时间: 15 Feb 2024 @ 04:49
回报率: -30.32%
上一信号: Feb 14 - 22:30
上一信号:
回报率: 2.01 %
Live Chart Being Loaded With Signals
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence...
Stats | |
---|---|
今日成交量 | 362 026 |
平均成交量 | 727 290 |
市值 | 573.30M |
EPS | $0 ( 2024-03-14 ) |
下一个收益日期 | ( $-0.470 ) 2024-05-09 |
Last Dividend | $0.800 ( 2019-09-10 ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.19 |
ATR14 | $0.0250 (0.52%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-29 | Marrazzo Jeffrey D | Buy | 250 000 | Stock Option (right to buy) |
2024-02-20 | Gv 2023 Gp, L.l.c. | Buy | 0 | Common Stock |
2024-02-25 | Gottesdiener Keith Michael | Buy | 100 000 | Stock Option (right to buy) |
2024-02-21 | Brudnick Richard | Buy | 135 747 | Stock Option (right to buy) |
2024-02-21 | Duffield Jeremy | Buy | 180 995 | Stock Option (right to buy) |
INSIDER POWER |
---|
34.78 |
Last 97 transactions |
Buy: 38 299 882 | Sell: 27 394 093 |
音量 相关性
First Trust Heitman 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
First Trust Heitman 相关性 - 货币/商品
First Trust Heitman 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $-4.65M (0.00 %) |
EPS: | $-2.18 |
FY | 2023 |
营收: | $0 |
毛利润: | $-4.65M (0.00 %) |
EPS: | $-2.18 |
FY | 2022 |
营收: | $5.21M |
毛利润: | $-6.80M (-130.60 %) |
EPS: | $-1.250 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-2.55 |
Financial Reports:
No articles found.
First Trust Heitman Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0900 | 2015-12-23 |
Last Dividend | $0.800 | 2019-09-10 |
Next Dividend | $0 | N/A |
Payout Date | 2019-09-12 | |
Next Payout Date | N/A | |
# dividends | 15 | -- |
Total Paid Out | $3.83 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.65 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
Unable to generate commentary due to missing data.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
LOMA | Dividend Knight | 2023-06-30 | Quarterly | 2 | 5.23% | 8.53 |
PHK | Dividend Royal | 2023-11-10 | Monthly | 22 | 6.88% | 8.50 |
JQC | Dividend Royal | 2023-11-14 | Monthly | 22 | 6.56% | 8.50 |
PCF | Dividend King | 2023-12-18 | Monthly | 38 | 7.05% | 8.50 |
PVL | Dividend King | 2023-11-15 | Monthly | 14 | 9.37% | 8.50 |
NCV | Dividend Royal | 2024-02-09 | Monthly | 22 | 7.68% | 8.50 |
SBR | Dividend Royal | 2023-11-14 | Monthly | 38 | 7.74% | 8.50 |
MTR | Dividend Diamond | 2023-10-30 | Monthly | 39 | 10.10% | 8.50 |
PDI | Dividend Royal | 2023-11-10 | Monthly | 13 | 7.86% | 8.50 |
ZTR | Dividend King | 2024-02-09 | Monthly | 37 | 8.35% | 8.50 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0 | 1.500 | 0 | 0 | [0 - 0.5] |
returnOnAssetsTTM | -1.022 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -0.937 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 2.53 | 0.800 | 2.33 | 1.864 | [1 - 3] |
quickRatioTTM | 2.16 | 0.800 | 2.02 | 1.617 | [0.8 - 2.5] |
cashRatioTTM | 0.737 | 1.500 | 7.02 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0703 | -1.500 | 8.83 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 440.77 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -1.699 | 2.00 | -0.566 | -1.132 | [0 - 30] |
freeCashFlowPerShareTTM | -1.788 | 2.00 | -0.894 | -1.788 | [0 - 20] |
debtEquityRatioTTM | 0.102 | -1.500 | 9.59 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0 | 1.000 | -3.33 | -3.33 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0 | 1.000 | -2.00 | -2.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -12.13 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 0.156 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -2.17 | 1.000 | -0.321 | 0 | [1 - 100] |
returnOnEquityTTM | -0.937 | 2.50 | -7.41 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -1.788 | 2.00 | -0.596 | -1.788 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -1.699 | 2.00 | -0.566 | -1.132 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.0624 | 1.500 | -2.92 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0 | 1.000 | -2.50 | 0 | [0.1 - 0.5] |
Total Score | -1.952 |
First Trust Heitman
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。